This presentation provides and overview of market access considerations for digital health innovations.
Greg Gregory, Ph.D., has a decade of strategy and management consulting experience working with top clients in the pharmaceutical and biotechnology industries and has a passion for rare diseases and orphan drugs. He has over a decade of biomedical research experience from leading research institutions.
He has 10+ years of experience in Market Access and Commercialization Strategies, Pricing and Reimbursement Strategies, Orphan Drugs, Vaccine, Oncology and Specialty Therapeutics Trade and Distribution Strategies, Hub Services Strategy, LOE, Payer Value Proposition, Vaccine Go-to-Market Strategy, and Digital Therapeutics. His areas of focus include working with rare disease and specialty products as well as gaining experience working across a range of therapeutic areas, including cardiovascular, hematology/oncology, immunology, respiratory, CNS, autoimmune disorders, vaccines, and digital therapeutics. He has delivered and/or managed over 200 consulting engagements for life-science companies ranging from start-up biotechs to top 5 pharmaceutical manufacturers. Greg is experienced in competitive payer dynamics, multi-indication access challenges, and adjunctive/combination therapies within orphan & oncology.
Greg leverages over a decade of biomedical research experience from leading research institutions. During his time in academia, his PhD and post-doctoral research furthered our understanding of the mechanisms contributing to several human diseases including the autoimmune disease multiple sclerosis and blood disorders such as thalassemia and thrombocytopenia.